Giorgio Montesi

Dr. Giorgio Montesi

Medical Biotechnologies, University of Siena, Siena, Tuscany, Italy
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
ACAnnalisa Ciabattini
Annalisa Ciabattini
GPGabiria Pastore
Gabiria Pastore
SLSimone Lucchesi
Simone Lucchesi
Giorgio MontesiGiorgio Montesi
Giorgio Montesi
SCSimone Costagli
Simone Costagli
DMDonata Medaglini
Donata Medaglini
The mRNA vaccines for SARS-CoV-2 have demonstrated efficacy and immunogenicity in the real-world setting. However, most of the research on vaccine immunogenicity has been centered on characterizing the antibody response, with limited exploration into the persistence of spike-specific memory B cells. Here we monitored the durability of the memory B cell response up to 9 months post-vaccination, and characterized the trajectory of spike-specific B cell phenotypes in healthy individuals who received two doses of the BNT162b2 vaccine. To profile the spike-specific B cell response, we applied the tSNE and Cytotree automated approaches. Spike-specific IgA+ and IgG+ plasmablasts and IgA+ activated cells were observed 7 days after the second dose and disappeared 3 months later, while subsets of spike-specific IgG+ resting memory B cells became predominant 9 months after vaccination, and they were capable of differentiating into spike-specific IgG secreting cells when restimulated in vitro. Other subsets of spike-specific B cells, such as IgM+ or unswitched IgM+IgD+ or IgG+ double negative/atypical cells, were also elicited by the BNT162b2 vaccine and persisted up to month 9. The analysis of circulating spike-specific IgG, IgA, and IgM was in line with the plasmablasts observed. The longitudinal analysis of the antigen-specific B cell response elicited by mRNA-based vaccines provides valuable insights into our understanding of the immunogenicity of this novel vaccine platform destined for future widespread use, and it can help in guiding future decisions and vaccination schedules.

8 July 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
Giorgio MontesiGiorgio Montesi
Giorgio Montesi
SCSimone Costagli
Simone Costagli
SLSimone Lucchesi
Simone Lucchesi
JPJacopo Polvere
Jacopo Polvere
Fabio FiorinoFabio Fiorino
Fabio Fiorino
ACAnnalisa Ciabattini
Annalisa Ciabattini
Background The spread of SARS-CoV-2 Omicron variant and its subvariants, highly transmissible but responsible of milder disease, has increased unreported infection cases. Identifying unaware infected individuals is crucial for estimating the true prevalence of infection and evaluating the breadth of hybrid immunity. In this study, this challenge was addressed by applying several Machine Learning approaches. Methods A group of 116 participants, vaccinated against SARS-CoV-2, was enrolled in the IMMUNO_COV study at Siena University Hospital, Italy. Blood samples were collected before and six months after third vaccine dose. Machine Learning analysis, involving dimensionality reduction techniques, unsupervised clustering methods and classification models, were applied to serological data including antibody responses specific for wild type SARS-CoV-2 strain as well as Delta, Omicron BA.1 and Omicron BA.2 variants. Spike- and nucleocapsid-specific B cells were also assessed in each participant. Results Using dimensionality reduction and unsupervised clustering, participants are grouped into high- and low-responders, with infected participants mainly distributed within the high-responders. Implementation of a consensus-based approach, including k-NN, RF, and SVM models, identifies 14 participants unaware of previous infection. Their immunological profile, characterized by strong spike- and nucleocapsid-specific humoral and B cell responses, significantly differs from that of non-infected participants. Conclusions Machine Learning approaches are applied to identify participants unaware of prior infection and to dissect their hybrid immunity profiles. Based on serological data, this cost-effective method can be a valuable tool for estimating the true prevalence of infection, improving comprehension of immune responses elicited by vaccination alone or combined with infection, and tailoring public health interventions.

17 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
ACAnnalisa Ciabattini
Annalisa Ciabattini
GPGabiria Pastore
Gabiria Pastore
SLSimone Lucchesi
Simone Lucchesi
Giorgio MontesiGiorgio Montesi
Giorgio Montesi
SCSimone Costagli
Simone Costagli
DMDonata Medaglini
Donata Medaglini
The mRNA vaccines for SARS-CoV-2 have demonstrated efficacy and immunogenicity in the re-al-world setting. However, most of the research on vaccine immunogenicity has been centered on characterizing the antibody response, with limited exploration into the persistence of spike-specific memory B cell response. Here we monitored the durability of the memory B cell response and characterize the trajectory of spike-specific B cell phenotypes in healthy individuals who have received two doses of the BNT162b2 vaccine up to 9 months post-vaccination. To profile the spike-specific B cell response we applied the tSNE and Cytotree automated approaches. Our data showed the induction of spike-specific IgA+ and IgG+ plasmablasts and IgA+ activated cells 7 days after the second dose which disappeared 3 months later, while subsets of spike-specific IgG+ resting memory B cells became predominant 9 months after vaccination, and they were capable to differentiate into spike-specific IgG secreting cells when in vitro restimulated. Other subsets of spike-specific B cells, such as IgM+ or unswitched IgM+IgD+ or IgG+ double negative/atypical cells, were also elicited by the BNT162b2 vaccine and persisted up to month 9. The analysis of circulating spike-specific IgG, IgA and IgM was in line with the plasmablasts observed. The longitudinal analysis of the antigen-specific B cell response elicited by mRNA-based vaccines provides valuable insights into our understanding of the immunogenicity of this novel vaccine platform destined to a future widespread use, and it is crucial in guiding future decisions and vaccination schedules.

28 November 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JPJacopo Polvere
Jacopo Polvere
SLSimone Lucchesi
Simone Lucchesi
Giorgio MontesiGiorgio Montesi
Giorgio Montesi
Fabio FiorinoFabio Fiorino
Fabio Fiorino
GPGabiria Pastore
Gabiria Pastore
ACAnnalisa Ciabattini
Annalisa Ciabattini
Long-term persistence of spike-specific memory B cells (MBC) upon mRNA SARS-CoV-2 vaccination remains poorly explored in people living with HIV (PLWH). We

4 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KBKehinde Adebayo Babatunde
Kehinde Adebayo Babatunde
MNMtakai Ngara
Mtakai Ngara
PMPaola Martinez Murillo
Paola Martinez Murillo
BSBibin Subramanian
Bibin Subramanian
AHAlex Hopke
Alex Hopke
PMPierre-Yves Mantel
Pierre-Yves Mantel
Summary: Malaria caused by Plasmodium falciparum ( Pf ) compromise innate immunity, yet the underlying mechanisms remain elusive. The immune dysregulation caused by the parasite may lead to bacterial superinfections and increase mortality. We reveal that Pf exploits extracellular vesicles (EVs) secreted by infected red blood cells (iRBC-EVs) to deliver host-derived miR451a to human neutrophils, impairing their antimicrobial defences. Neutrophil phagocytosis of iRBC-EVs suppresses reactive oxygen species (ROS) production and compromised microbicidal activity against Salmonella typhimurium . Microfluidic assays show that miR451a transfer significantly disrupts neutrophil chemotaxis and swarming upon microbial challenge. Transcriptomic profiling indicates that EVs and miR451a reprogram neutrophil gene expression, notably upregulating ferroptosis-related genes, suggesting a role in further impairing immune responses. We have uncovered a novel mechanism of iRBC-EVs-induced neutrophil immune suppression and provide insights into increased susceptibility to bacterial superinfections in malaria. These findings have implications for therapeutic strategies aimed at mitigating bacterial superinfections and sepsis in malaria-endemic regions.

31 October 2026 in Public Health
Verified
Journal Article
Open access
GMGabriel dos Santos Mouta
Gabriel dos Santos Mouta
SFSarah P.R. Freire
Sarah P.R. Freire
Giorgio MontesiGiorgio Montesi
Giorgio Montesi
LSLuis G.E. Souza
Luis G.E. Souza
JAJosé D.A. Araújo
José D.A. Araújo
Helder NakayaHelder Nakaya
Helder Nakaya